Orthocell Secures Approval to sell Remplirâ„¢ to the U.S. Department of Defence Hospital Network

Orthocell logo (PRNewsfoto/Orthocell Ltd)

  • Orthocell receives approval for Remplirâ„¢ to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, comprising:
    • 51 DoD military hospitals; and
    • 170 Veterans Affairs (VA) medical centres
  • For context, Orthocell has already secured 32 Value Analysis Committee (VAC) approvals providing access to over 115 hospitals, with a further 57 VAC applications currently pending approval[1]
  • Orthocell will now leverage its existing U.S. distributor network to target military and VA surgeons operating within these hospital systems. The Company's distributor network currently covers 17 states
  • This approval comes at a time when Orthocell is seeing clear evidence of increasing commercialisation and revenue momentum in the U.S. market
  • Remplir has already demonstrated its value in conflict-related injuries in Ukraine, with multiple surgical procedures performed, highlighting its suitability for the types of trauma commonly encountered within military healthcare systems

PERTH, Australia, April 16, 2026 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce it has secured approval for its Remplirâ„¢ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks.

Recommended for you